The clinical activity of cyclin-dependent kinase 4 (CDK4)/CDK6 inhibitors has largely been attributed to their capacity to block the proliferation of tumour cells, but increasing evidence discussed in this Review suggests that these inhibitors also have immunomodulatory effects that promote antitumour immune responses.
- Giulia Petroni
- Silvia C. Formenti
- Lorenzo Galluzzi
